Nuwellis, Inc. (NUWE) is a medical technology company specializing in the development and commercialization of innovative fluid management solutions and services. Nuwellis, previously known as CHF Solutions, Inc, is headquartered in the United States and was incorporated in 1999. The company offers products primarily for treating fluid overload, typically caused by health conditions such as heart failure and critical care conditions. By focusing on fluid overload, the company addresses a significant unmet medical need in the most efficient, patient-centric manner.
The company's flagship product, Aquadex SmartFlow, stands at the core of its offering. This system provides an ultrafiltration process for the removal of salt and water in patients who fail to respond adequately to diuretic treatment. By applying this high-precision fluid management technology, it helps to remove excess fluid from the body, providing patients with a more comfortable experience and potentially reducing their time spent in the hospital.
In addition to the Aquadex system, Nuwellis provides comprehensive therapy implementation and clinical education services. The company’s medical, sales, and marketing teams work continuously to educate clinicians and healthcare professionals about the advantages of the Aquadex system, offering support for hospitals and clinics to implement this versatile therapy successfully.
Nuwellis Inc’s commitment to innovation and patient care has placed it as a leader in fluid management. The company has distinguished itself with its dedication to providing significant potential clinical benefits to patients with fluid overload, primarily caused by heart failure and other critical illnesses such as acute decompensated heart failure.
Nuwellis has expressed its vision to make a meaningful difference in the lives of patients suffering from fluid overload and improve healthcare services around the world. To achieve this, the company is continuously striving to make improvements in fluid management while prioritizing safety and patient comfort. This, in combination with the company's comprehensive support services, creates a strong value proposition for the healthcare industry.
In conclusion, Nuwellis Inc continues its commitment to medical technology innovation, coupled with high levels of service and support. The focus of the company on patient well-being and efficient, effective therapy has helped it to position as a strong emerging player in the field of fluid management. Whether it's through its revolutionary Aquadex system, active education programs, or dedicated customer support, Nuwellis Inc is uniquely positioned to make an impact on patient health and improve the treatment of fluid overload.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Nuwellis, Inc. and Atrility Medical, Inc. have announced a co-promotion and distribution agreement for Atrility's AtriAmp® device, expanding Nuwellis' pediatric and critical care portfolio. The agreement includes an initial six-month co-promotion phase, with Nuwellis potentially becoming the exclusive U.S. distributor. The AtriAmp device, which is FDA-cleared for adult and pediatric patients, provides continuous real-time atrial electrograms for patients with temporary epicardial pacing wires, complementing Nuwellis' focus on critical care medicine.
Nuwellis announced that a study published in Frontiers in Pediatrics confirms epoprostenol is a safe and feasible anticoagulant for pediatric Aquadex ultrafiltration therapy. The retrospective review of 46 children at UPMC Children’s Hospital showed no bleeding complications and stable platelet counts over 52 treatment courses. This finding is crucial for critically ill pediatric patients who cannot tolerate conventional anticoagulants, expanding the Aquadex system's use in pediatric intensive care.
Nuwellis, Inc. (NASDAQ:NUWE) reported mixed Q2 2026 results, with revenue growing 14% year-over-year to $2.0M, meeting expectations. However, the company significantly missed on EPS with a loss of $26.64 per share and a net loss of $4.8M. Investors reacted negatively, causing NUWE shares to drop 3.5%.